Navigation Links
Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification

r the long-lasting benefit to the patient is maintained, demonstrating disease modification, or if the patient drops back to the level of patients on placebo for the duration of the study. In a staggered start design, one group of patients receives the active study drug for the entire study period, while a second group initially receives placebo and then later is given the active drug. If the second group fails to "catch up" in the level of performance of the first group, this is taken to be evidence for a disease modifying effect of the drug. Unfortunately, these designs are difficult to implement and have rarely been used in clinical trials as they are complicated by very long study durations, leading to high dropout rates that introduce biased results, as well as presenting ethical concerns unacceptable to patients and their families.

A team of biostatisticians and mathematicians at Myriad, led by Suzanne Hendrix, Ph.D., Sasha Gutin, Ph.D., and Scott Horton, has proposed an alternative strategy designated the "Natural History Staggered Start" analysis, that compares the slopes of decline of drug treated patients with those of patients receiving placebo and corrects for the severity of disease at baseline. The mathematical analysis presented at the Alzheimer's Association AD Prevention Conference demonstrates that this trial analysis methodology is mathematically equivalent to the "Staggered Start" and "Randomized Withdrawal" designs and provides the same level of evidence of a disease-modifying drug effect in a clinical trial that is not subject to the above-mentioned complications, bias and ethical challenges of the previous designs.

"We are excited about this persuasive mathematical comparison of clinical trial designs," said Adrian Hobden, PhD, President of Myriad Pharmaceuticals, Inc. "We believe that this mathematical proof, coupled with the Flurizan trial design may strengthen the Company's position with the FDA in favor of a disease modificat
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Myriad Genetics Presents Tumor Origin Technology at AACR
2. Myriad Genetics Presents Azixas Mode of Action at AACR
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
5. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
(Date:7/21/2014)... , July 21, 2014 Thoratec Corporation ... device-based mechanical circulatory support therapies to save, support and ... its operating results for the second quarter of fiscal ... company will hold a conference call to discuss its ... parties, at 1:30 p.m., Pacific Daylight Time (4:30 p.m., ...
(Date:7/21/2014)... /PRNewswire-iReach/ -- Top Brooklyn Pediatrician Dr. ... article, which suggests that caffeine may be dangerous, according ... A few decades ago parents ... but now it happens rather frequently, according to an ... in the journal Pediatrics, discussed a new study, which ...
(Date:7/21/2014)... 2014 UBM Medica US announces that ... community for primary care clinicians offers a photo collection ... victims of a variety of summer scourges.  ... a host of medical menaces: poison ivy, tick-borne infections, ... the highlights covered on Consultantlive,s topic center that includes ...
Breaking Medicine Technology:Thoratec Schedules Second Quarter Conference Call, Webcast 2Dr. Michael Gabriel a Brooklyn Pediatrician Comments on an Article, Which Suggests Caffeine May Be Dangerous for Children 2ConsultantLive Presents Special Coverage of Summer Scourges 2ConsultantLive Presents Special Coverage of Summer Scourges 3
... May 5, 2011 IRIDEX Corporation (Nasdaq: IRIX ) ... sales and improved financial results for the first quarter ended April ... $0.06 per diluted share, up from $0.5 million or $0.05 per ... ophthalmology sales grew 10%. Total sales increased to $11.2 million ...
... Inc. (Nasdaq: BIOD ) today reported financial results for ... Fiscal Year 2011 Financial Results Biodel reported a net ... million, or $0.21 per share, compared to a net loss of ... the prior year. Research and development expenses were ...
Cached Medicine Technology:IRIDEX Reports Growing Revenue and Profits in 2011 First Quarter 2IRIDEX Reports Growing Revenue and Profits in 2011 First Quarter 3IRIDEX Reports Growing Revenue and Profits in 2011 First Quarter 4IRIDEX Reports Growing Revenue and Profits in 2011 First Quarter 5Biodel Reports Second Quarter Fiscal Year 2011 Financial Results 2Biodel Reports Second Quarter Fiscal Year 2011 Financial Results 3Biodel Reports Second Quarter Fiscal Year 2011 Financial Results 4Biodel Reports Second Quarter Fiscal Year 2011 Financial Results 5Biodel Reports Second Quarter Fiscal Year 2011 Financial Results 6
(Date:7/22/2014)... Pompano Beach, Florida (PRWEB) July 22, 2014 ... and alcohol treatment center located in Pompano ... of approval from the Joint Commission, an independent ... the United States. Accreditation signifies that the quality ... the Joint Commission standards for safety and performance. ...
(Date:7/22/2014)... Coral, FL (PRWEB) July 22, 2014 ... has opened registration for multiple upcoming real estate investing ... These potentially life-changing events are designed to introduce people ... using in the Canadian market. , A total of ... over a period of three weeks. The goal is ...
(Date:7/22/2014)... 22, 2014 2014 ST. JOHN’S, CONSUMER ... to announce the 2014 Top Service Providers in their ... extend heartfelt congratulations to all this year’s winners; your ... of St. John’s. , Each year across Canada, Consumer ... responses of thousands of consumers and businesses. All winners ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Recently, 2014quinceaneradresses.com, ... has announced its latest assortment of blue and ... promotional prices on these special Quinceanera gowns, hoping to ... before July 30 can get a discounted price, up ... very glad to announce these new items. As one ...
(Date:7/22/2014)... Carolina (PRWEB) July 22, 2014 One woman ... solution managed to lose 20 pounds. Unfortunately, the weight loss ... nauseated for the duration of her time using the pill, ... woman experienced heart flutters and insomnia as a result of ... a heart attack at the age of 37 because of ...
Breaking Medicine News(10 mins):Health News:Florida Drug and Alcohol Addiction Treatment Center Receives Joint Commission Seal of Approval 2Health News:Florida Drug and Alcohol Addiction Treatment Center Receives Joint Commission Seal of Approval 3Health News:Brick Buy Brick Announces Multiple 1-Day Real Estate Workshops Coming to Toronto 2Health News:2014 St. John's Consumer Choice Award Winners 2Health News:2014 St. John's Consumer Choice Award Winners 3Health News:2014 St. John's Consumer Choice Award Winners 4Health News:Blue and White Quinceanera Dresses at Low Prices Offered by 2014quinceaneradresses.com 2Health News:SlimPlate System Urge Women to Shun Controversial Weight Loss Pills for Healthier Methods Like Portion Control 2
... the best way to fix the broken health care system is a ... from an employment based insurance system. , ... Brookfield, Wisconsin (PRWEB) November ... to fix the broken health care system is a complete overhaul, they ...
... two radio frequency modes into one device. The Accent Dual Mode RF ... on both shallow and deep tissue depths. The technology is the latest ... and Laser Center. , ... New York, NY (PRWEB) November 13, 2008 ...
... 13 TheraQuest Biosciences, Inc. a,development stage ... U.S.,Food and Drug Administration (FDA) has accepted ... its abuse deterrent extended release,strong opioid. TQ-1015 ... deterrent technology., Najib Babul, PharmD, Chief ...
... of members, SEIU officials shut down,California offices ahead ... Caregivers who work in,California hospitals, nursing homes, and ... offices of their national union, the Service,Employees International ... United Healthcare Workers-West (UHW), a,local union that has ...
... helps prevent malaria, ALEPE, Cote d,Ivoire, Nov. ... and their partners worldwide helped Cote d,Ivoire,s,National Program ... health,campaign November 11 that will vaccinate 3.5 million ... the country with bed nets to,stop the spread ...
... 12 Amilpar,(BOVESPA: AMIL3, Bloomberg: AMIL3 BZ and Reuters: AMIL3.SA), ... for the third quarter of 2008., 3rd Quarter ... at the end of September, up 18.2% ... than the previous quarter. -- Adjusted Operating Revenues totaled ...
Cached Medicine News:Health News:Employers Want National Approach to Health Care—Still Believe Employer-Based System Works Best: New Survey Looks At Attitudes toward Health Care Reform and Major Health Care Issues. 2Health News:Employers Want National Approach to Health Care—Still Believe Employer-Based System Works Best: New Survey Looks At Attitudes toward Health Care Reform and Major Health Care Issues. 3Health News:Accent Dual Mode Skin Tightening Laser is Latest Offering from Juva Skin Center 2Health News:TheraQuest's IND for Abuse Deterrent Strong Opioid (TQ-1015) Accepted by FDA 2Health News:Healthcare Workers Picket Their National Union to Protect Their Voice for Patients 2Health News:Photo: United Methodist Church, Partners Launch Life-Saving Campaign in Cote d'Ivoire 2Health News:Amilpar Revenues Grow 28% in the First 9 Months of 2008 and 4.5% Over Previous Quarter 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: